

1 Evaluation of a One Health public health program based on minimum inputs to control *Taenia*
2 *solium* in Madagascar

3 Diana Edithe Andria-Mananjara^{1*}, Modestine Raliniaina¹, Mihaja Rakotoarinoro¹, José A Nely²,
4 Nivohanitra Razafindraibe^{3,4}, Sylvia Noromanana Ramiandrasoa⁵, Betthelhein Ramahefasoa³,
5 Valisoa Claude Rakotoarison¹, Paul R. Torgerson⁶, Eric Cardinale^{7,8}, Harena Rasamoelina-
6 Andriamanivo⁴, Glenn Edosoa⁹, Agnès Fleury^{10,11}, Kabemba E. Mwape¹², Bernadette Abela¹³,
7 Marshall W. Lightowers¹⁴, Meritxell Donadeu^{14,15*}

8

9 ¹National Center for Applied Research on Rural Development (FOFIFA), BP04 Rue Farafaty
10 Ampandrianomby, Antananarivo, Madagascar

11 ²Ministry of Health of Madagascar, Building CHU-SSPA, ex-HIS Analakely, Tananarive,
12 Madagascar

13 ³Directorate of Veterinary Services, Ministry of Agriculture and Livestock, Ampandrianomby,
14 Madagascar

15 ⁴CDC-One Health Indian Ocean-Indian Ocean Commission/SEGA-One Health Network

16 ⁵Consultant, Lot ITP22, Andrambato Itaosy, Antananarivo 102, Madagascar

17 ⁶Section of Epidemiology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland

18 ⁷CIRAD, Montpellier, France

19 ⁸University of La Réunion

20 ⁹WHO Country Office, United Nations Common Building, Galaxy Area, Andraharo, BP 362,
21 Antananarivo 101, Madagascar

22 ¹⁰ Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones
23 Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México

24 ¹¹ Clínica de neurocisticercosis, Instituto Nacional de Neurología y Neurocirugía, Ciudad de
25 México, México

26 ¹²Department of Clinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka,
27 Zambia

28 ¹³Department of the Control of Neglected Tropical Diseases, World Health Organization,
29 Geneva, Switzerland

30 ¹⁴Department of Biosciences, Melbourne Veterinary School, University of Melbourne, 250
31 Princes Highway, Werribee, Victoria, Australia

32 ¹⁵Initiative for Neglected Animal Diseases (INAND), Midrand, South Africa

33 Corresponding authors:

34 *dianaandria21@gmail.com (DEAM); Meritxell.Donadeu@gmail.com (MD)

35 **Abstract**

36 Cysticercosis in humans caused by the parasite *Taenia solium* is one of the World Health
37 Organization's Neglected Tropical Diseases. The parasite is transmitted between the human host
38 and pigs. Efforts to prevent the disease have relied mainly on treatment of people with
39 anthelmintics. However to date there is no practical and effective control method that has been
40 delivered as a public health program. Here we describe a large-scale, minimum inputs *T. solium*
41 control program implemented as a public health program in Madagascar. Initially pigs were
42 vaccinated for porcine cysticercosis and medicated with oxfendazole, after which only young
43 piglets and pigs imported into the program area were targeted for interventions. After piglet
44 interventions were in place and on-going, a single mass drug administration (MDA) was
45 delivered to the human population with a taeniicide. The outcomes were assessed one year after
46 the human treatment, by comparing pre-and post-intervention levels of human *T. solium* taeniasis
47 and porcine cysticercosis caused by *T. solium*. Over a twenty-two-month period, 96,735 pig
48 vaccinations were delivered and during the MDA, 117,216 people received taeniicide. Ninety
49 percent of the pig population were receiving vaccination and medication at the end of the
50 intervention period. Coverage of the eligible human population by the MDA was 62.5%. Human
51 taeniasis was found to be 1.25% prior to the MDA and 0.6% one year after the MDA. Prior to the
52 intervention 30.8% of slaughter-age pigs had viable *T. solium* infection whereas no viable
53 infection was detected in any pig treated in the program. The program successfully demonstrated
54 effective control of *T. solium* transmission using minimum inputs and delivered as a public health
55 program. Sustained control and expansion of the program could potentially lead to the
56 elimination of the disease being a public health problem in Madagascar.

57

58 **Author summary**

59 Cysticercosis caused by the cestode parasite *Taenia solium* is one of the World Health
60 Organization's neglected tropical diseases. We implemented One Health cysticercosis control as a
61 public health program in a highly endemic region of Madagascar. The program was designed to
62 require minimum inputs while achieving maximum impacts on control within a short period of
63 time. Pigs were vaccinated with the TSOL18 vaccine and simultaneously treated with oxfendazole.
64 Over a 2-year period, piglets 2-3 months of age were treated. After pig vaccination practices were
65 established, the human population received a single treatment with a taeniicide. The program was
66 evaluated by assessment of porcine cysticercosis and human taeniasis before and 12 months after
67 the human mass drug administration. More than 95,000 pig vaccinations were delivered and
68 117,000 persons received taeniicide. The intervention entirely eliminated viable porcine
69 cysticercosis in slaughter-age pigs that had received treatment as well as reducing human taeniasis.
70 Continuation and expansion of the program would have the potential to eliminate *T. solium* from
71 the program area, or even from the entire country.

72

73 **Introduction**

74 Neurocysticercosis (NCC) is an infection of the central nervous system caused by the larval stage
75 of a zoonotic parasite, *Taenia solium* [1]. It is prevalent in many parts of the world where risk
76 factors for the parasite's life cycle are present, such as poverty, lack of hygiene and sanitation,
77 and the presence of free-roaming pigs [1]. As a result, many low and middle income countries,
78 including Madagascar, are endemic to *T. solium* [2, 3], and NCC is a leading cause of epilepsy in
79 the population [4].

80 NCC is considered a preventable and potentially eradicable neglected tropical disease [5]. So far,
81 attempts to control transmission of *T. solium* have relied mainly on preventive chemotherapy in
82 humans using either praziquantel or niclosamide [6-9]. Another tool available for the control of
83 *T. solium* is the combined use of the TSOL18 (Cysvax®) porcine cysticercosis vaccine together
84 with a single treatment with oxfendazole in pigs. The vaccine has proved to be safe and efficient,
85 and the combination with oxfendazole has been found to eliminate parasite transmission by the
86 treated pigs in field trials undertaken in Nepal, Cameroon and Uganda [10-12].

87 One Health research projects based on mass drug administration (MDA) and/or targeted
88 chemotherapy in combination with other One Health measures (mainly pig vaccination and/or
89 treatment) have achieved a reduction in *T. solium* transmission [13-17]. However, the approaches
90 used have been neither practical, sustainable nor able to be implemented successfully as public
91 health programs. There are currently no validated models for the control of the parasite.

92 Here we sought to evaluate the effectiveness of a *T. solium* control strategy requiring minimum
93 inputs with the potential to lead to a substantial and sustainable reduction in parasite
94 transmission, and delivered as a public health program by the Veterinary Services of the Ministry
95 of Livestock and the Ministry of Public Health of Madagascar. Principal components of the
96 program involved vaccination and treatment of young piglets, and a single round of MDA in the
97 human population after pig vaccination had been well established. Outcomes were assessed by
98 comparing pre and post intervention levels of human *T. solium* taeniasis and porcine
99 cysticercosis.

100 **Methods**


101 **Ethics statement**

102 Intervention and assessment protocols were designed and implemented in compliance with
103 ethical approvals for the study granted by the Madagascar Ministry for Public Health Ethics
104 Committee for Biomedical Research No. 088-MSANP/SG/AMM/CERBM and by the Malagasy
105 National Animal Ethics Committee, No. 001-21/CENA.

106 **Study area and timeline**

107 The control program was implemented from August 2021 to August 2023 in a single contiguous
108 area in central Madagascar comprising nine municipalities in two districts of Vakinankaratra
109 region, Betafo and Mandoto (Fig 1). The area comprises approximately 420 villages (hamlets)
110 spread over 84 fokontany (the lowest administrative unit), 205,197 inhabitants in 45,539

111 households [18] and an estimated 27,000 pigs. The most important economic activity among 93%
112 of the population is mixed cropping with livestock farming [18]. Pig farming is one the major
113 livestock activities of households. It is used as a means of livelihood and a source of savings for
114 small scale farmers [19]. The program area was selected because the prevalence of human
115 cysticercosis in the region was relatively high [20]. It is also one of the main suppliers of pigs for
116 Antsirabe (the largest city in the region) and the capital of Madagascar, Antananarivo [21], and
117 cases of porcine cysticercosis were seen frequently in Vakinankaratra compared to other regions
118 of the central highlands [22].



119

Fig 1. *Taenia solium* One Health control program implementation areas in Madagascar

120 Program design and rationale

121 Interventions to interrupt *T. solium* transmission were undertaken in the two obligate hosts of the
122 parasite, pigs and humans. Implementations were designed as One Health interdependent actions
123 and included training of actors, advocacy and social mobilization to maximize the involvement of
124 the relevant stakeholders.

125 The timings of the interventions were a key component of the program design. Because humans
126 after receiving the MDA can get infected or re-infected with *T. solium* after ingesting
127 contaminated pork (as there is no immunity to the tapeworm), the first step was to reduce the risk
128 of infection in humans by reducing the prevalence of the disease in the pig population. Therefore,
129 the first step was to vaccinate and treat the pigs to minimise the risk of infection or reinfection in
130 humans. Only when that risk was minimised by having the pig population vaccinated and
131 treated, then the MDA was to be conducted. However, because of the likely imperfect coverage
132 of the MDA, and the potential risk of tapeworm eggs surviving in the environment, the
133 vaccination of piglets and incoming pigs continued for a year after the MDA.

134 While the implementation was based on activities conducted as a public health program
135 (therefore implemented by existing staff linked to the Ministry of Public Health or the Veterinary

136 Services), the evaluation was conducted as a research project so as to obtain accurate measures of
137 the impact of the intervention on *T. solium* transmission. The local coordination and supervision
138 were provided by the National Center for Applied Research on Rural Development (FOFIFA).

139 **Pig intervention**

140 Intervention activities in pigs were undertaken between October 2021 and August 2023. Initially
141 a census of the pig population in the program areas was conducted to determine the number of
142 pigs. Subsequently, pigs in the area were vaccinated with the TSOL18 vaccine (Cysvax® from
143 Indian Immunologicals Limited) and, simultaneously, received an oral treatment with
144 oxfendazole (Oxfenvet® from Indian Immunologicals Limited). Interventions in the pig
145 population were undertaken by the staff of the Ministry of Livestock through the Veterinary
146 Services Directorate, the sanitary veterinarians and their animal health agents (vaccinators).

147 At the start of the program, the intervention targeted all the pigs in the population. Inclusion
148 criteria were animals ≥ 2 months of age, showing no obvious signs of sickness and not pregnant
149 or lactating. The animals received two immunizations, approximately one month apart, with the
150 Cysvax® vaccine and, at the time of the second immunization they also received treatment with
151 oxfendazole at 30 mg/kg. Subsequently, throughout the program, newborn piglets (at ≥ 2 months
152 of age) and any pigs imported into the program area received both Cysvax vaccination and
153 oxfendazole treatment twice, at least 1 month apart (Fig 2). At the time of the first vaccination
154 and treatment, the animals were tagged with a button tag in one ear. At the time of the second
155 vaccination and treatment, the button tag was marked with indelible pen. Vaccinators visited the
156 villages approximately on a monthly basis, and farmers having newborn piglets or imported
157 animals were identified by the farmer themselves, the Chief of the fokontany or neighbouring
158 farmers. The program aimed to identify and treat any animals which did not initially receive
159 treatment for some reason during the following monthly visits to the farms. The interval between
160 vaccinations is not critical and intervals of 2-4 months between primary and secondary
161 immunization provide as good, or better, response to the vaccine [23]. The strategy was efficient
162 in targeting piglets but less reliably for older animals as they were often roaming in the fields and
163 difficult to reach.

164 Pig vaccination and treatment coverage was not measured precisely, as it would have required
165 greater resources and logistics than were available. From August 2022, it was decided to use a
166 proxy measure, by asking the vaccinators to record the vaccination status of the pigs they meet
167 during their monthly vaccinations. Because the vaccinators were only going to the households
168 where they knew there were pigs to be vaccinated (as learned from previous visits, the Chief of
169 the fokontany or other farms), they were not capturing the total population as they were not going
170 to households where, for example, all the pigs were already vaccinated. This is an imperfect
171 measure as pigs could have been missed, but it helped to identify areas where the coverage was
172 'lower' and where additional awareness efforts were required.

173 Vaccinators were required to maintain strict biosecurity measures to prevent the spread of pig
174 diseases, in particular African and Classical swine fevers. Disinfection of boots, overalls, lassoes,
175 and other equipment with Virokil® was mandatory before entering and after leaving a farm.
176 Vaccine and oxfendazole were administered using single use disposable syringes. Any waste was

177 stored in special bags and transported to the veterinarians, who in turn disposed of it in an
178 appropriate manner.


179 **Human intervention**

180 A single MDA was undertaken in the human population once the intervention in the pig
181 population was fully established (August 2022, Fig 2). The MDA was initially planned for
182 December 2021, but due to adverse events with a child receiving praziquantel during a MDA
183 program for schistosomiasis in a nearby district, the Ministry of Public Health delayed all the
184 MDA interventions until further training and preventive measures were put in place. For that
185 reason, the MDA was not undertaken until August 2022. The Ministry of Public Health through
186 its communicable disease control department and the local medical staff (regional and district
187 responsible for neglected tropical diseases, chiefs of health centers and community health
188 agents), undertook the MDA campaign in all the eligible population over 5 years of age. The
189 main drug used was praziquantel (Cesol™ from Merck or Biltricide® from Bayer). As MDA
190 with praziquantel was already part of the Ministry of Public Health's annual program for
191 treatment of schistosomiasis (co-endemic with *Taenia solium* in this region), the MDA was
192 conducted by the Ministry of Public Health in synergy with their MDA campaign against
193 schistosomiasis. Children between 5 and 15 years of age targeted by the schistosomiasis program,
194 received praziquantel at 40mg/kg. Additionally, the children in Betafo district, also received
195 mebendazole (500mg, Vermox® from Johnson & Johnson) as part of the Ministry of Public
196 Health program to control soil-transmitted helminths. People 15 years old and over, were treated
197 with praziquantel at 10mg/kg as a taeniocide. Prior to the MDA, a series of training and activities
198 were undertaken to prevent and minimise neurological adverse events (Nely et al. submitted).
199 Eligibility criteria for praziquantel treatment in people over 5 years of age were: non pregnant
200 women, women who had been breastfeeding for more than 3 months, and people without
201 symptoms or signs compatible with NCC such as seizures and epilepsy or chronic headache.
202 Those exhibiting symptoms or signs compatible with NCC were treated with niclosamide
203 (Yomesan®, Bayer) at a dose of 1g for children from 5 to 6 years of age, and 2g for children over
204 6 years and adults.

205 Active and passive surveillance were conducted to monitor and quickly identify and manage any
206 possible adverse events in people who had participated in the MDA (Nely et al. submitted). Local
207 staff were trained and appropriate medicines were made available at health centers to deal with
208 side effects, such as neurological events, drug allergies, etc.

209

Fig 2. One Health model for the control of *Taenia solium* in Madagascar. Fig 2A shows the original design, and Fig 2B shows the actual implementation after the MDA had to be delayed.



210 Training, monitoring and auditing

211 Prior to the interventions, training was undertaken for those involved in activities related to
212 animals or humans.

213 Veterinarians and vaccinators were trained in vaccination procedures, maintenance of cold chain,
214 identification of vaccinated animals, oral drug treatment, coverage data collection, and
215 biosecurity measures. Messages and attitudes to transmit to farmers who may have been initially
216 reluctant to take part of the campaign were also covered during the training. During the
217 vaccination campaign, vaccinators were supervised and audited by local veterinarians as well as
218 by FOFIFA staff.

219 Those involved in the human intervention received cascade training. Modules covered a refresher
220 on the disease complex, standard operating procedures for the MDA (which is already part of the
221 annual Ministry program), key messages to increase participation, coverage data collection,
222 active surveillance of NCC cases and potential adverse reactions, and management of adverse
223 events (Nely et al., submitted). Monitoring and supervision of activities were undertaken by the
224 program's senior staff pre and post-MDA campaign.

225 Community sensitization

226 Social mobilization was a key component for this program. The local authorities were the first
227 ones to be involved, and with their cooperation awareness campaigns were undertaken to
228 facilitate access to beneficiaries and maximize their participation either in the animal or human
229 interventions. Traditional singers were recruited to compose awareness-raising songs related to
230 the fight against *T. solium* and to perform the songs in local tours in the municipalities covered by
231 the program. In addition, radio spots were strategically broadcasted on local channels. The key

232 messages for these two types of sensitizations were related to the parasite's transmission, the
233 importance of the fight against *T. solium*, encouragement of farmers to participate in the pig
234 vaccination, encouragement of people to participate in the MDA, and the clarification of any
235 negative rumours circulating about the interventions.

236 Posters were produced in local language and posted in the villages or used at community
237 meetings. The program used the WHO/WOAH/FAO *T. solium* poster on the cycle of the parasite
238 and the possible ways of control [24]. Other posters on the identification and management of
239 adverse events were also prepared and used during the MDA (Nely et al, submitted).

240 **Data collection**

241 Data from all interventions were recorded through paper-based forms. For pig interventions, data
242 was recorded monthly by vaccinators and focused on the number of animals in each farm, the
243 number of vaccinated animals according to the number of immunizations provided, and the
244 number of non-vaccinated animals per category (< 2 months, pregnant sow, lactating sow). Local
245 supervising veterinarians collected all data recorded and made a monthly report for the senior
246 staff.

247 For the MDA, data collected related to the demographic characteristic of the person who received
248 the drug, the presence of signs compatible with NCC, the drug administered, adverse events, the
249 clinical signs linked to the adverse event, and the treatment received.

250 **Program evaluation**

251 The program was evaluated by determining changes in the prevalence of porcine cysticercosis
252 and the prevalence of human *T. solium* taeniasis. The objective was always to conduct the endline
253 evaluation one year after the MDA, so because the MDA was delayed, the final evaluation was
254 also delayed. Baseline and endline evaluations were conducted, respectively, in August 2021 and
255 August 2023 for porcine cysticercosis. Evaluations for *T. solium* taeniasis were carried in October
256 2021 (repeated in December 2021) and August 2023.

257 Porcine cysticercosis was determined by detailed necropsy examination on 104 slaughter-age
258 pigs selected randomly and purchased from the population. The same 26 fokontany randomly
259 selected for sampling at baseline were also sampled at endline evaluation. The sample size for
260 necropsy assessment (104 animals) was calculated from a population of 45,000 pigs (as per the
261 latest official census) distributed in 20 villages, each ranging from 350 animals upwards per
262 village, with the samples assumed to be aggregated. The expected initial necropsy prevalence was
263 15%. Samples size was calculated with a power of 90% and 99% confidence interval.

264 Calculations were done in R (version 3.6.0) via Monte-Carlo simulations. Necropsies were
265 undertaken as previously described [25]. Briefly, the animals were brought to a central veterinary
266 facility in Antananarivo where local butchers prepared the carcasses. The muscles of the right-
267 hand side of the carcass as well as the masseters, tongue, full diaphragm and heart were dissected
268 from the bodies and sliced by hand at approximately 3mm intervals to reveal all cysts. Where no
269 cysts were identified, the left-hand side of the carcass was assessed for possible infection in a
270 similar way. Cysts were recorded as either viable or non-viable and their numbers were counted
271 to determine the level of infection. For the endline assessments, 104 animals were randomly

272 selected (independently of their vaccination and treatment status), and an additional 16 slaughter-
273 age pigs were selected at random from those in the population that had not received any
274 vaccination or oxfendazole, to have a total of 50 non vaccinated or treated pigs.

275 The prevalence of human *T. solium* taeniasis was determined by Kato-Katz thick smear as
276 described in the World Health Organization (WHO) Bench aid for the diagnosis of intestinal
277 procedures [26]. The first evaluation conducted in October 2021 only found four positive
278 samples, which was not congruent with the high level of infection in pigs determined during the
279 baseline necropsies. Therefore, the sampling design was adjusted, and a new purposive sampling
280 was conducted, targeting only villages in which roaming pigs and deficient sanitation were
281 present, but randomly selecting the people within those villages. The number of samples per
282 village was also proportional to the number of pigs in the village, and not to the number of
283 people, as due to the cycle of the parasite, it is less likely that there is active transmission in the
284 larger towns in which there are fewer (or no) roaming pigs and better sanitation. In summary, for
285 the new baseline and the final evaluation, faecal samples from 960 people were purposively
286 sampled (according to the size of the pig population) from throughout 26 fokontany. For the
287 baseline evaluation, one smear was prepared for most of the samples, while 2 smears were
288 examined for 78 samples. Confirmation of the *Taenia* species present in Kato-Katz positive
289 samples was performed by PCR and sequencing of a segment of the small subunit of
290 mitochondrial ribosomal RNA (rrnS) gene, as described in Lightowers et al. [27]. All endline
291 examinations were undertaken on duplicate smears. Sample size was calculated from an
292 estimated target population of 190,000 which would detect a reduction in prevalence from 1.8%
293 to <0.1%, with a power of 90% and confidence level of 99%. Calculations were done in R via
294 Monte-Carlo simulations.

295 **Data Analysis**

296 All collected data were entered into Microsoft Office Excel ® spreadsheets. Statistical analyses
297 were performed using R 4.3.0 software.

298 The coverage rate for pig interventions were calculated based on the number of pigs that received
299 one dose or two doses of Cysvax and the total number of eligible pigs in the area. Pigs that were
300 considered not to pose a risk for *T. solium* transmission were those that were less than 2 months
301 of age, those that had received one treatment (vaccine and oxfendazole) within the previous 2
302 months and those that had received two treatments (vaccine and oxfendazole).

303 Levels of porcine cysticercosis in slaughter-age pigs in the intervention area before the
304 intervention and in non-vaccinated or treated animals at the time of the final evaluation were
305 compared using a negative binomial general linear model.

306 For human interventions, the coverage was calculated based on the number of people who
307 received treatment during the MDA and the number of eligible targeted population. Categorical
308 outcomes, which are the prevalences of porcine cysticercosis with viable cysts and human
309 taeniasis before and after the interventions were compared between study groups using Chi
310 square test /Fisher's Exact test. A p value <0.05 was considered statistically significant.

311 Results


312 3.1 Initial pig census

313 The number of pigs in the intervention area was assessed to be 27,071 belonging to 12,006 pig
314 farmers, representing an estimated average of 2 pigs per farm. The majority of farmers allowed
315 their pigs to roam freely. Some pigs went with the farmers to the field during their agricultural
316 activities, while others roam around the villages to search for food. Most of the time, breeding
317 pigs and their piglets, as well as pigs entering the fattening phase, are left free to roam, and some
318 will only be confined in a pigsty at the end of the fattening phase.

319 3.2 Pig treatment and vaccination

320 The initial vaccination and treatment of the pig population (from October to November 2021)
321 reached 19,135 pigs for the first immunization, representing 70.68% of the pig population
322 determined by the census prior to the beginning of vaccinations. For the second immunizations
323 the number of pigs vaccinated decreased to 8,120 of those previously vaccinated ($p < 0.001$ 95%
324 CI 0.32 - 0.52). This change was associated with the appearance or unsubstantiated and often
325 outrageous rumours. Efforts were made subsequently to identify and vaccinate those pigs that
326 missed the second scheduled immunization during the following visits, however as these animals
327 were typically in the fields and hence unavailable when the vaccinators visited the farms.

328 Vaccinations that subsequently targeted piglets > 2 months and new imported pigs increased
329 progressively in number throughout the intervention period (Fig 3). On average, 3,309 (SD \pm
330 1,434) vaccinations per month were carried out. The number of vaccinations per month increased
331 fourfold between January 2022 and August 2023. In total, 96,735 vaccinations were delivered
332 during the program.



333


Fig 3: Number of pig vaccination and treatments recorded per month during the *T. solium* intervention program. Piglets > 2 months and any pigs imported into the program area were targeted for vaccination and treatment, twice each, throughout the intervention period.

334 Data on the coverage rate of vaccination and treatments was obtained from vaccinators from
335 August 2022 onwards and also from the random selection of pigs used for the endline evaluation
336 necropsies.

337 On average, vaccinators identified approximately 7,000 pigs (eligible and ineligible, vaccinated
338 and unvaccinated) per month. The coverage per month and the proportion of the total pig
339 population that were considered to pose no risk for transmission of *T. solium* varied from one
340 fokontany to another. Detailed records of vaccination coverage show a progressive increase in the
341 percentage of the 84 fokontany achieving a coverage over 75% with >92% coverage achieved in
342 the final months of the program (Fig 4).

343 From August 2022 when proxy detailed coverage was obtained until the end of the year (5
344 months), 11 fokontany out of the 84 had a coverage <50% (seven fokontany on one occasion,
345 three fokontany on two occasions, and one fokontany on 3 occasions). In comparison, during the
346 8 months of 2023, only one fokontany had once a coverage below 50%.

347



348 **Fig 4. Coverage of pig vaccination and treatment over time.** Proportion of fokontany that
349 achieved a coverage $\geq 75\%$ of the pig population for vaccination and treatment as recorded by the
350 pig vaccinators.

351

352 The data for vaccination coverage from the random selection of pigs during the endline
353 evaluation was 67.30%, which indicated that among 104 randomly selected pigs, 70 pigs were
354 vaccinated and 34 of pigs were not vaccinated.

355 **3.3 Human intervention**

356 In total, 117,216 persons were treated during the MDA, which represented 62.52% of the eligible
357 population (187,490 out of 231,755 total population). Significant differences in treatment
358 coverage rates were observed between municipalities (Table 1). Fidirana municipality had the
359 highest number of people treated, with a coverage rate approaching 90%, while Soavina
360 represented the area with the lowest participation, with 40% of the population. There was no
361 significant difference observed between the proportion of children under 15 treated and the
362 proportion of people over 15 years of age that participated in the MDA ($p>0.05$). Among the
363 persons treated, 615 received niclosamide as they were identified as having symptoms or signs
364 compatible with NCC, which represent 0.52% of the treated population. Among persons treated
365 with niclosamide, the number of people more than 15 years old was higher than the number of
366 children less than 15 years old ($p<0,0001$).

Table 1. Population treatment data for the taeniicide MDA intervention

Municipalities areas	Total Population	Children 5 to 14 years old	People > 15 years old	Children 5 to 14 years old treated (%)		People > 15 years old treated (%)		MDA coverage (%)
				Praziquantel	Niclosamide	Praziquantel	Niclosamide	
Ambohimasina	26,727	7,350	14,272	4,443 (40.48)	6 (0.05)	6,489 (59.13)	37 (0.34)	10,975(50.76) ^a
Inanantonana	17,012	4,678	9,084	3,357 (33.44)	0	6,681 (66.56)	0	10,038 (72.94) ^b
Ambohimanambola	31,037	8,535	16,574	5,633 (37.12)	7 (0.05)	9,423 (62.09)	113 (0.74)	15,176 (60.44) ^c
Soavina	19,046	5,238	10,171	2,723 (43.92)	1 (0.02)	3,458 (55.77)	18 (0.29)	6,200 (40.24) ^d
Antohobe	17,877	4,917	9,546	3,217 (39.93)	15 (0.19)	4,790 (59.46)	34 (0.42)	8,056 (55.70) ^e
Ankazomiriotra	41,800	11,495	22,322	6,440 (36.17)	34 (0.19)	11,217 (63.00)	113 (0.63)	17,804 (52.65) ^f
Betsohana	12,188	3,352	6,508	2,779 (32.06)	17 (0.20)	5,823 (67.18)	49 (0.57)	8,668 (87.91) ^g
Fidirana	38,308	10,534	20,456	9,641 (34.65)	20 (0.07)	18,101 (65.05)	65 (0.23)	27,827 (89.79) ^h
Vinany	27,760	7,634	14,824	4,205 (33.72)	10 (0.08)	8,181 (65.59)	76 (0.61)	12,472 (55.53) ⁱ
TOTAL	231,755	63,733	123,757	42,438 (36.20)	110 (0.09) ^j	74,163 (63.27)	505 (0.43) ^k	117,216 (62.52)
				42,548 (66.76)		77,668 (60.33)		

369 There was one case of a severe neurological adverse event. A 13-year-old child among those
370 treated with praziquantel, presented in the evening of the first day of MDA headache, which
371 became stronger during the night; the next day, he vomited and had seizures. This severe adverse
372 event was promptly identified and managed as per established protocols (Nely et al submitted). A
373 CT scan revealed three parenchymal NCC lesions. The child received appropriate medical care,
374 there have been no recurrence of seizures and is leading a normal life.

375 **3.4 Program evaluation - pigs**

376 The randomly selected slaughter-age animals assessed at the endline necropsies comprised 70
377 vaccinated and treated pigs and 34 untreated pigs (Table 2). Among the vaccinated animals, no
378 viable *T. solium* cysts were found. Five treated and vaccinated animals were found to have non-
379 viable lesions in the muscles (4 animals with up to 10 lesions, one with 83 lesions). Among the
380 slaughter-age pigs that had not been vaccinated and treated, 8 (23.5%) were found to be infected
381 with viable *T. solium* cysts. Comparison of the prevalence of viable *T. solium* infection between
382 baseline and final showed a significant difference in the prevalence of porcine cysticercosis
383 ($p < 0.001$). Comparison of the entire pig population between baseline and final evaluations
384 showed a statistically significant decrease in viable infections with *T. solium* from 30.77 to
385 7.69%.

386 Among the total of 50 slaughter-age pigs that were evaluated by necropsy and had not received
387 any vaccination or oxfendazole, that is the 34 pigs randomly selected for the final evaluation plus
388 the additional 16 randomly selected amongst the non-vaccinated or treated, 15 (30%) were found
389 to have *T. solium* cysticerci in their muscles (either viable or non-viable).

Table 2. Necropsy results of the baseline and endline program evaluations

<i>Evaluation</i>	<i>Baseline</i>	<i>Endline</i>	
Status of pigs	Non vaccinated	Vaccinated	Non vaccinated
Number of pigs	104	70	34
Number with viable cysts			
1 - 10 cysts	8		6
11 - 100 cysts	8		1
101 - 500 cysts	11		1
>500 cysts	5		0
Number with only non-viable cysts	5	5	1
Number with no cysts	67	65	25

Prevalence with viable cysts % (95% CI)	30.77 ^c (22.08-40.57)	0 ^a (0-5.13)	23.53 ^b (10.74-41.17)
		7,69 ^d (3.37-14.59)	

390 a vs b ; a vs c ; c vs d p<0,001 c vs b p=0.42

391 3.4 Program evaluation - humans

392 Assessment of 960 people randomly selected from the population, Kato-Katz identified taeniasis
393 in 12 persons (1.25%) at baseline [27] and 6 persons (0.6%) one year after the single MDA
394 intervention. The difference was not statistically significant (p=0.13). Of the total 18 positive
395 fecal samples, 15 (9 from baseline, and 6 from final evaluation) were able to be confirmed to
396 species level by copro-PCR and DNA sequencing; all were confirmed as *T. solium*.

397 Among the samples tested at baseline, all the egg-positive samples were identified to be positive
398 among the samples examined in a single Kato Katz slide except for one, which was identified
399 among the 78 baseline samples tested by 2 slides, and it was positive in both slides. The six
400 samples identified as Kato-Katz positive during the final evaluations were all positive in both
401 slides tested.

402 Discussion

403 The strategy of piglet vaccination and oxfendazole treatment eliminated the potential for *T. solium*
404 transmission by the pigs that participated in the program. Of 70 treated, slaughter-age animals that
405 were examined by slicing the entire striated musculature of the animals, no infection with viable
406 *T. solium* was identified in any animal. Five animals were identified with non-viable cysts only.
407 The *T. solium* vaccine targets an antigen uniquely associated with the oncosphere life cycle stage
408 [28] and is not believed to affect cysticerci that may have established in the tissues prior to
409 vaccination. However, the simultaneous treatment with oxfendazole kills any such pre-existing
410 cysts in the muscles [29, 30]. For this reason, the five animals detected with only non-viable lesions
411 in vaccinated and treated pigs at the endline necropsies are interpreted as being animals that had
412 been exposed to infection prior to treatment [29, 30]. The important point is that these non-viable
413 lesions present no risk of transmission of infection. By comparison, prior to the interventions 30.8%
414 of similarly aged animals had viable *T. solium* infection in their musculature. The finding that some
415 of the piglets were likely to have been exposed to *T. solium* prior to being vaccinated and treated
416 highlights the importance of delivering the oxfendazole dose in full to the piglets; failure to do so
417 could potentially result in the presence of viable cysts in vaccinated animals (due to infections
418 established prior to vaccination) which could appear as vaccine failures.

419 A highly significant reduction was observed in the number of *T. solium* cysts (viable or non-viable)
420 in non-vaccinated or treated animals that were evaluated at the final evaluation, compared to the
421 animals assessed at baseline (Table 3, p = 0.0005). This is interpreted as reflecting a reduction in
422 environmental contamination with *T. solium* eggs in the intervention area.

423

424 Table 3. Reduction in environmental contamination with *T. solium* measured as a proxy in non-
425 vaccinated pigs. The number of *T. solium* cysticerci (viable and non-viable) was evaluated by
426 necropsy in non-vaccinated or treated pigs before and after the intervention.

427

	Number of pigs evaluated	Number of pigs with cysts	Mean number of <i>T. solium</i> cysts in infected animals	Confidence interval
Baseline	104	37	464 ^a	226-1195
Final evaluation	50	9	26 ^b	10-93

428 ^a vs ^b p=0.00005

429

430 There was a seasonal variation in the coverage of pig treatments, influenced by other farming
431 activities which resulted in the farmers leaving the house very early and not being available to
432 facilitate the vaccination, or by the farmers taking the pigs with them to the fields, such as during
433 the months of December and January which is the rice transplanting season, or harvesting time in
434 June. Throughout the program the coverage rate of the pig population for treatments steadily
435 increased (Fig 4). Soon after the program began, rumours began to circulate that caused many
436 farmers to decline to have their animals vaccinated. For example, it was believed by some that
437 the program was a conspiracy by the government to stop the farmers from breeding local breeds
438 of pigs. It also coincided with a high anti-vaccine general attitude in the population due to the
439 ongoing issues concerning human vaccination for COVID. The farmers rarely vaccinated their
440 animals for any purpose even though epidemics of Classical Swine Fever cause mass pig
441 mortality, and hence they have a rudimentary understanding of vaccines, if any. Our use of ear
442 tags to indicated vaccinated animals was initially also a source of concern for the farmers as it
443 was not usual. Continuing efforts throughout the program to educate the farmers and dispel the
444 rumours saw the dissipation of negative rumours and a steadily increasing rate of participation.
445 The fact that treated animals were often judged by farmers to be growing faster helped improve
446 the participation rate. This could be due to the effect of the oxfendazole treatment on nematode
447 and other parasitic infections [31, 32].

448 The endline assessment in pigs was undertaken in slaughter age animals, more than 8 months of
449 age and generally around 12 months of age (born between September 2022 and January 2023).
450 These animals were raised when coverage of the pig population was 67% (as judged by the
451 randomly selected slaughter-age animals taken for endline necropsy). Hence the 75% decrease in
452 the prevalence of viable *T. solium* infection in the pig population (30.8% to 7.7%) was achieved in
453 animals born between September 2022 and January 2023 when coverage was around 67%. Given
454 that the vaccination and treatment of piglets eliminated *T. solium* transmission at the time of
455 slaughter-age in all 70 animals that were assessed and had participated in the program, it could be
456 expected that the program would have achieved a 90% reduction in transmission through pigs had
457 it been possible to undertake necropsies at slaughter-age for animals born later in the program when
458 the piglet coverage rate had increased to 90%. A program of continued piglet vaccination and

459 treatment and similar intervention of animals imported into the program area, would maintain
460 control of *T. solium* transmission indefinitely. In Madagascar it may be possible to eliminate
461 transmission by extending the program to the entire country.

462 The intervention program met a major challenge with implementing the planned MDA in
463 humans. The plan was to undertake the MDA a short time after the entire pig population had been
464 vaccinated and treated, and piglet vaccinations were well established and continuing. However, a
465 serious adverse event in 2021 during the routine Malagasy schistosomiasis MDA program with
466 praziquantel resulted in a child's death in a district nearby the program area, delaying the MDA of
467 this program until further measures were put in place. This situation also had an impact on the
468 population's participation in the program's MDA. The population coverage for the MDA was
469 62.5% while the objective was to reach >75% of the population. This being the case, it was not
470 surprising to find that *T. solium* taeniasis remained present in the population at the endline
471 assessments and transmission continued to non-treated pigs (as evidenced by the rate of infection
472 in the 50 non vaccinated pigs). An earlier taeniasis MDA program in Madagascar, in a nearby
473 area undertaken prior to the occurrence of the aforementioned adverse event achieved a 95%
474 coverage [9], suggesting that the population is not averse to participating in MDA programs. Had
475 there been more time between the adverse event that occurred during the schistosomiasis program
476 and our MDA, a higher coverage of the population is likely to have been achieved.

477 An unanticipated but valuable outcome of our program has been the development of protocols,
478 resources and a strategy to minimize the potential for adverse events occurring due to MDA
479 being undertaken with praziquantel in an area that is, or may be, endemic for *T. solium*. These
480 resources are available through the WHO [33, 34] and the measures are discussed in full by Nely
481 et al. (submitted).

482 A feature of this *T. solium* control program was that it was implemented not as a research project,
483 but as a public health program, carried out by the two responsible ministries in Madagascar
484 (Ministry of Public Health and Ministry of Livestock). In this way, it was implemented by
485 existing and already responsible structures. It was provided to all the people in the control region,
486 without cost. The involvement of the Ministries was planned with a view to appropriation and
487 sustainability, as well as extension once the program was completed and demonstrated to be
488 successful. Although the program was implemented as a public health program, it was evaluated
489 as if it had been a research project so as to obtain an accurate evaluation of its impacts.

490 An additional outcome of the program, was an improved relationship between the Ministries and
491 other relevant stakeholders, reflecting the benefits of strengthening the One Health systems for
492 future collaborations and preparedness for future challenges.

493 The program was designed to require minimum inputs and to have a rapid impact, so as to
494 maximize the feasibility of the program being implemented in other *T. solium* endemic regions of
495 Madagascar, and elsewhere. With minimum inputs we refer to only one MDA and one
496 intervention in the whole pig population, followed only by intervention in piglets and incoming
497 new pigs. The fact that the whole pig population is only dealt with at the start of the program, and
498 from then onwards only piglets and new incoming pigs were treated, facilitated the field work, as
499 having to catch large roaming pigs is not an easy task. The program provided MDA treatment

500 drugs through a donation via the WHO and the program funding supported the cost of the
501 vaccine, oxfendazole and vaccinators who delivered to program to the animals. Without these
502 resources from external donors it is unlikely that control of this neglected zoonosis could be
503 undertaken in Madagascar, or elsewhere, where full transmission of the parasite occurs.

504 The public health program implemented here achieved the complete cessation in *T. solium*
505 transmission by the animals involved in the program and potentially a 90% reduction in
506 transmission within 2 years which could be accelerated by achieving higher coverage in the
507 MDA. This reduction would be sustainable through a continuation of the treatments in piglets,
508 which could be reduced or terminated after *T. solium* taeniasis levels no longer provided a source
509 of new infections. A cost-benefit analysis of this program is currently underway to provide the
510 further evidence needed for validation. In addition, in the case of Madagascar, a map of high-risk
511 areas for *T. solium* is being prepared so as to provide decision-makers tools for any further
512 implementation of this public good control program.

513 In conclusion, this minimum input One Health *T. solium* control program significantly reduced
514 parasite transmission. A higher MDA coverage (which is known to be feasible in the program
515 area) and 90% piglet coverage would likely deliver a near cessation in transmission, which could
516 be sustained by continued piglet treatments. The intervention was delivered as a public health
517 program and therefore reflected the real-life challenges when implementing these types of
518 programs in the field, providing a possible model for future *T. solium* control programs.

519 **Acknowledgement**

520 We are very grateful to the local authorities at all levels who were involved in the implementation
521 and the sensitization of communities program for their invaluable input. The cooperation of all
522 inhabitants and pigs farmers in the area who participated in the interventions both in animal and
523 human side is very much appreciated. And the program couldn't have been implemented without
524 the hard work and support from all the health agents, community health agents, and medical staff
525 supporting the MDA, as well as all the pig vaccinators, and veterinarians involved in the pig
526 activities. The success of the program is a credit to them. Support is acknowledge from the
527 Ministry of Health, the Ministry of Agriculture and Livestock and the Ministry of Scientific
528 Research and Higher Education.

529

530 **References**

531

- 532 1. Garcia HH, Gonzalez AE, Gilman RH. *Taenia solium* cysticercosis and its impact in
533 neurological disease. Clin Microbiol Rev. 2020;33(3). Epub 2020/05/29. doi:
534 10.1128/CMR.00085-19. PubMed PMID: 32461308; PubMed Central PMCID:
535 PMC7254859.
- 536 2. Donadeu M, Lightowers MW, Fahrion AS, Kessels J, Abela-Ridder B. *Taenia solium*:
537 WHO endemicity map update. Wkly Epidemiol Rec. 2016;91(49-50):595-9. PubMed PMID:
538 27966846.

- 539 3. Carod JF, Mauny F, Parmentier AL, Desmarests M, Rakotondrazaka M, Brembilla A, et al.
540 Hyperendemicity of cysticercosis in Madagascar: Novel insights from school children
541 population-based antigen prevalence study. PLoS One. 2021;16(10):e0258035. Epub
542 2021/10/02. doi: 10.1371/journal.pone.0258035. PubMed PMID: 34597322; PubMed
543 Central PMCID: PMC8486106.
- 544 4. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, et al. A
545 systematic review of the frequency of neurocysticercosis with a focus on people with
546 epilepsy. PLoS Negl Trop Dis. 2010;4(11):e870. doi: 10.1371/journal.pntd.0000870.
547 PubMed PMID: 21072231; PubMed Central PMCID: PMC2970544.
- 548 5. Anonymus. Update: International Task Force for Disease Eradication. Morbidity and
549 Mortality Weekly Report. 1992;41(691):697-8.
- 550 6. Cruz M, Davis A, Dixon H, Pawlowski ZS, Proano J. Operational studies on the control of
551 *Taenia solium* taeniasis/cysticercosis in Ecuador. Bull World Health Organ. 1989;67(4):401-
552 7. Epub 1989/01/01. PubMed PMID: 2805217; PubMed Central PMCID:
553 PMC2491261.
- 554 7. Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillan R, Flisser A. Mass treatment
555 against human taeniasis for the control of cysticercosis: a population-based intervention
556 study. Trans R Soc Trop Med Hyg. 2000;94(1):85-9. Epub 2000/04/05. PubMed PMID:
557 10748908.
- 558 8. Allan JC, Velasquez-Tohom M, Fletes C, Torres-Alvarez R, Lopez-Virula G, Yurrita P, et al.
559 Mass chemotherapy for intestinal *Taenia solium* infection: effect on prevalence in humans
560 and pigs. Trans R Soc Trop Med Hyg. 1997;91(5):595-8. Epub 1998/02/17. PubMed PMID:
561 9463679.
- 562 9. Ramiandrasoa NS, Ravoniarimbina P, Solofoniaina AR, Andrianjafy Rakotomanga IP,
563 Andrianarisoa SH, Molia S, et al. Impact of a 3-year mass drug administration pilot project
564 for taeniasis control in Madagascar. PLoS Negl Trop Dis. 2020;14(9):e0008653. Epub
565 2020/09/19. doi: 10.1371/journal.pntd.0008653. PubMed PMID: 32946447; PubMed Central
566 PMCID: PMC7500903.
- 567 10. Poudel I, Sah K, Subedi S, Kumar Singh D, Kushwaha P, Colston A, et al. Implementation
568 of a practical and effective pilot intervention against transmission of *Taenia solium* by pigs
569 in the Banke district of Nepal. PLoS Negl Trop Dis. 2019;13(2):e0006838. Epub 2019/02/26.
570 doi: 10.1371/journal.pntd.0006838. PubMed PMID: 30802248; PubMed Central PMCID:
571 PMC6405169.
- 572 11. Assana E, Kyngdon CT, Gauci CG, Geerts S, Dorny P, De Deken R, et al. Elimination of
573 *Taenia solium* transmission to pigs in a field trial of the TSOL18 vaccine in Cameroon. Int J
574 Parasitol. 2010;40(5):515-9. doi: 10.1016/j.ijpara.2010.01.006. PubMed PMID: 20138046;
575 PubMed Central PMCID: PMC2856920.
- 576 12. Nsadh Z, Rutebarika C, Ayebazibwe C, Aloys B, Mwanja M, Poole EJ, et al. Control trial
577 of porcine cysticercosis in Uganda using a combination of the TSOL18 vaccination and
578 oxfendazole. Infect Dis Poverty. 2021;10(1):34. Epub 2021/03/22. doi: 10.1186/s40249-021-
579 00823-6. PubMed PMID: 33743828; PubMed Central PMCID: PMC7981864.

- 580 13. Garcia HH, Gonzalez AE, Tsang VC, O'Neal SE, Llanos-Zavalaga F, Gonzalvez G, et al.
581 Elimination of *Taenia solium* transmission in northern Peru. *N Engl J Med*.
582 2016;374(24):2335-44. doi: 10.1056/NEJMoa1515520. PubMed PMID: 27305193; PubMed
583 Central PMCID: PMCPMC4962610.
- 584 14. Gabriel S, Mwape KE, Hobbs EC, Devleesschauwer B, Van Damme I, Zulu G, et al.
585 Evidence for potential elimination of active *Taenia solium* transmission in Africa? *N Engl J*
586 *Med*. 2020;383(4):396-7. Epub 2020/07/24. doi: 10.1056/NEJMc1909955. PubMed PMID:
587 32699455; PubMed Central PMCID: PMCPMC7289521.
- 588 15. O'Neal SE, Moyano LM, Ayvar V, Rodriguez S, Gavidia C, Wilkins PP, et al. Ring-
589 screening to control endemic transmission of *Taenia solium*. *PLoS Negl Trop Dis*.
590 2014;8(9):e3125. Epub 2014/09/12. doi: 10.1371/journal.pntd.0003125. PubMed PMID:
591 25210748; PubMed Central PMCID: PMCPMC4161340.
- 592 16. Beam M, Spencer A, Fernandez L, Atto R, Muro C, Vilchez P, et al. Barriers to participation
593 in a community-based program to control transmission of *Taenia solium* in Peru. *Am J Trop*
594 *Med Hyg*. 2018. Epub 2018/04/18. doi: 10.4269/ajtmh.17-0929. PubMed PMID: 29663901.
- 595 17. O'Neal SE, Pray IW, Vilchez P, Gamboa R, Muro C, Moyano LM, et al. Geographically
596 targeted interventions versus mass drug administration to control *Taenia solium*
597 cysticercosis, Peru. *Emerging infectious diseases*. 2021;27(9):2389-98. doi:
598 10.3201/eid2709.203349.
- 599 18. INSTAT. Troisième Recensement Général de la Population et de l'Habitation (RGPH-3).
600 Résultats Globaux du Recensement Général de la Population et de l'Habitation de 2018 de
601 Madagascar (RGPH-3). Tome 1 and 2, 2020.
- 602 19. Rakotoarisoa J, Bélières J-F, Salgado P. Agricultural intensification in Madagascar: public
603 policies and pathways of farms in the Vakinankaratra region. *PROIntens Africa Initiative*
604 [Internet]. 2016. Available from: <https://agritrop.cirad.fr/582242/>.
- 605 20. Zafindraibe NJ, Ralalarinivo J, Rakotoniaina AI, Maeder MN, Andrianarivelo MR,
606 Contamin B, et al. [Seroprevalence of cysticercosis and associated risk factors in a group of
607 patients examined at the Regional Referral Hospital in Antsirabe]. *Pan Afr Med J*.
608 2017;28:260. Epub 2018/06/09. doi: 10.11604/pamj.2017.28.260.10463. PubMed PMID:
609 29881503; PubMed Central PMCID: PMCPMC5989193.
- 610 21. Sourisseau J-M, Rasolofo P, Bélières J-F, Guengant J-P, Ramanitriniony HK, Bourgeois R,
611 et al. Diagnostic territorial de la région du Vakinankaratra à Madagascar 2016. Available
612 from: <https://agritrop.cirad.fr/580518/>.
- 613 22. Rasamoelina-Andriamanivo H, Porphyre V, Jambou R. Control of cysticercosis in
614 Madagascar: beware of the pitfalls. *Trends Parasitol*. 2013;29(11):538-47. Epub 2013/10/23.
615 doi: 10.1016/j.pt.2013.09.002. PubMed PMID: 24145061.
- 616 23. Lightowers MW, Donadeu M, Elaiyaraja M, Maithal K, Kumar KA, Gauci CG, et al.
617 Anamnestic responses in pigs to the *Taenia solium* TSOL18 vaccine and implications for
618 control strategies. *Parasitology*. 2016;143(4):416-20. doi: 10.1017/S0031182016000202.
619 PubMed PMID: 26892239.

- 620 24. World Health Organization, World Organisation for Animal Health, Food and Agriculture
621 Organization of the United Nations (FAO). How to prevent the pork tapeworm? A neglected
622 parasitic infection caused by *Taenia solium* - Poster. 2022.
- 623 25. Mananjara DEA, Rakotoarinoro M, Rakotoarison VC, Raliniaina M, Razafindraibe NP,
624 Ravonirina C, et al. Confirmation by necropsy of a high prevalence of porcine cysticercosis
625 in a rural district of Madagascar. *Parasitology*. 2023;150(9):852-7. Epub 2023/07/27. doi:
626 10.1017/S0031182023000653. PubMed PMID: 37496390; PubMed Central PMCID:
627 PMC10478050.
- 628 26. World Health Organization. Bench Aid for the diagnosis of intestinal parasites - Second
629 edition. Geneva: World Health Organization; 2019.
- 630 27. Lightowers MW, Mananjara DEA, Rakotoarinoro M, Rakotoarison VC, Raliniaina M,
631 Rasamoelina-Andriamanivo H, et al. Comparison of Kato-Katz, PCR and coproantigen for
632 the diagnosis of *Taenia solium* taeniasis. *Parasitology*. 2023:1-7. Epub 2023/08/25. doi:
633 10.1017/S0031182023000690. PubMed PMID: 37621007.
- 634 28. Gauci CG, Ito A, Lightowers MW. Conservation of the vaccine antigen gene, TSOL18,
635 among genetically variant isolates of *Taenia solium*. *Mol Biochem Parasitol*.
636 2006;146(1):101-4. doi: 10.1016/j.molbiopara.2005.10.014. PubMed PMID: 16298439.
- 637 29. Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, et al. Time-response
638 curve of oxfendazole in the treatment of swine cysticercosis. *Am J Trop Med Hyg*.
639 1998;59(5):832-6. PubMed PMID: 9840607.
- 640 30. Sikasunge CS, Johansen MV, Willingham AL, 3rd, Leifsson PS, Phiri IK. *Taenia solium*
641 porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal
642 antigens after treatment with oxfendazole. *Vet Parasitol*. 2008;158(1-2):57-66. doi:
643 10.1016/j.vetpar.2008.08.014. PubMed PMID: 18834668.
- 644 31. Alvarez L, Saumell C, Fuse L, Moreno L, Ceballos L, Domingue G, et al. Efficacy of a
645 single high oxfendazole dose against gastrointestinal nematodes in naturally infected pigs.
646 *Vet Parasitol*. 2013;194(1):70-4. doi: 10.1016/j.vetpar.2013.01.003. PubMed PMID:
647 23357598.
- 648 32. Ortiz P, Terrones S, Cabrera M, Hoban C, Ceballos L, Moreno L, et al. Oxfendazole
649 flukicidal activity in pigs. *Acta Trop*. 2014;136:10-3. doi: 10.1016/j.actatropica.2014.03.024.
650 PubMed PMID: 24713198.
- 651 33. World Health Organization. Symptoms and signs compatible with neurocysticercosis in
652 relation to preventive chemotherapy 2023:[3 p.]. Available from:
653 <https://www.who.int/publications/i/item/9789240068117>.
- 654 34. World Health Organization. Early detection and management of neurological serious adverse
655 events in relation to the administration of anthelmintic medicines to people with
656 asymptomatic neurocysticercosis 2023:[8 p.]. Available from:
657 <https://www.who.int/publications/i/item/9789240068131>.